Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that SPARC-targeted zinc sulfide nanoparticles alleviate early brain injury in rat hemorrhage models, indicating a viable multi-target nanotherapeutic approach.
Subarachnoid hemorrhage (SAH) remains a devastating stroke subtype with high morbidity and mortality, largely due to complex early brain injury (EBI) within the first 72 h involving cerebral vasospasm (CVS), oxidative stress, and neuroinflammation. Existing therapies such as nimodipine offer limited protection and fail to address multiple injury pathways. Here, we report a SPARC-targeted albumin-based zinc sulfide nanoparticle (ZnS/BSA NPs) designed for lesion-specific delivery and multi-mechanistic therapy for SAH. We demonstrate that SPARC is significantly upregulated in both human and rat SAH brains, enabling active targeting of injured vasculature and crossing the blood–brain barrier (BBB). ZnS/BSA NPs exhibit good colloidal stability in serum-containing medium and pH-responsive release of Zn2+ and H2S. Mechanistically, Zn2+ suppresses Ca2+ influx/CaMKII activation to alleviate CVS; H2S activates NRF2/HO-1 to scavenge reactive oxygen/nitrogen species (RONS) and inhibits NF-κB/NLRP3 signaling to shift microglia from M1 to M2 polarization. Additionally, the NPs inhibit Caspase-1/GSDMD-mediated pyroptosis in microglia and suppress both Caspase-1/GSDMD-mediated pyroptosis and Bax/Caspase-3-mediated apoptosis in neurons, thereby preserving BBB integrity and reducing brain edema. In a rat SAH model, ZnS/BSA NPs significantly improved learning, memory, and motor function, outperforming nimodipine. This work highlights SPARC as a viable druggable target and represents a “targeted, multi-mechanistic” nanotherapeutic paradigm for EBI after SAH.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: